A vaccine to help prevent MenB in
​​​​​​​adolescents and young adults

TRUMENBA is a vaccine to help prevent MenB
(IMD caused by N. meningitidis serogroup B
bacteria), for use in individuals aged 10 through
​​​​​​​25 years. 

Even if you have, or your child has, already
been vaccinated against meningococcal
​​​​​​​meningitis, the vaccines may not have included
serogroup B – the most common serogroup
​​​​​​​associated with IMD in Canada. 

How does it work?

TRUMENBA targets a protein found in over 95% of bacteria that cause Meningitis B. It works by helping the body make antibodies (the body’s natural defenses), which protect individuals against this disease. These antibodies kill the bacteria that cause Meningitis B. 
If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them. 

How is it given?

Your healthcare professional will inject TRUMENBA into the upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.  



New NACI recommendation: 

NACI recommends that TRUMENBA may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, in a 2-dose schedule (0 and 6 months), to reduce the risk of invasive serogroup B meningococcal disease. 


Individuals at increased risk of IMD may include persons with functional or anatomic asplenia, including sickle cell disease; persons with congenital  complement, properdin, factor D or primary antibody deficiencies; persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab and individuals with HIV.

A vaccine for meningitis B prevention.

Thank you for signing up for your
TRUMENBA vaccine reminder!